Trial Profile
Pilot study of the tolerability of nivolumab for relapsed or residual haematological malignancies after allogeneic haematopoietic stem cell transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Haematological malignancies; Hodgkin's disease; Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms NIVALLO
- 21 Sep 2021 Planned End Date changed from 20 May 2022 to 1 Mar 2022.
- 21 Sep 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Mar 2022.
- 03 Aug 2021 Planned End Date changed from 1 Mar 2021 to 20 May 2022.